Spyre Therapeutics (SYRE) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to 0.9.
- Spyre Therapeutics' Equity Ratio rose 1600.18% to 0.9 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9, marking a year-over-year increase of 1600.18%. This contributed to the annual value of 0.85 for FY2024, which is 5809.12% up from last year.
- Per Spyre Therapeutics' latest filing, its Equity Ratio stood at 0.9 for Q3 2025, which was up 1600.18% from 0.85 recorded in Q2 2025.
- Over the past 5 years, Spyre Therapeutics' Equity Ratio peaked at 0.9 during Q3 2025, and registered a low of 1.18 during Q3 2023.
- Over the past 5 years, Spyre Therapeutics' median Equity Ratio value was 0.76 (recorded in 2021), while the average stood at 0.56.
- Its Equity Ratio has fluctuated over the past 5 years, first crashed by 26048.29% in 2023, then surged by 20082.59% in 2024.
- Quarter analysis of 5 years shows Spyre Therapeutics' Equity Ratio stood at 0.76 in 2021, then decreased by 7.4% to 0.71 in 2022, then decreased by 23.87% to 0.54 in 2023, then skyrocketed by 58.09% to 0.85 in 2024, then increased by 5.98% to 0.9 in 2025.
- Its Equity Ratio was 0.9 in Q3 2025, compared to 0.85 in Q2 2025 and 0.85 in Q1 2025.